8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 28, 2004

Halozyme Therapeutics, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
11588 Sorrento Valley Road, Suite 17, San Diego, California		92121
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On October 22, 2004, Halozyme Therapeutics, Inc. (the "Company") received notice from the American Stock Exchange ("AMEX") that it had approved the Company’s application to transfer the listing of the Company’s securities from the OTC Bulletin Board. The Company’s securities are expected to commence trading on AMEX at the opening of business on November 1, 2004. The stock trading symbol for the Company will change to "HTI." Please see the attached Press Release dated October 25, 2004.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit -- Description
----------------------------
99.1 -- Press Release issued by the Company on October 25, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
October 28, 2004	By:	Jonathan E. Lim, M.D.
		Name: Jonathan E. Lim, M.D.
		Title: President and Chief Executive Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release issued by the Company on October 25, 2004

EX-99.1

Exhibit 99.1

Halozyme Therapeutics Approved for Listing on the American Stock Exchange
SAN DIEGO, Oct 25, 2004 /PRNewswire-FirstCall via COMTEX/ — Halozyme Therapeutics, Inc. (OTC Bulletin Board: HZYM), a development stage biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that its common stock has been approved for listing on the American Stock Exchange (“Amex”). Halozyme’s common stock is expected to commence trading on the Amex under the symbol “HTI” on Monday, November 1, 2004.

“We are very excited about moving to the American Stock Exchange. It is indicative of the significant progress that Halozyme has made over the past few months, including raising $13.9 million in a private placement, signing an exclusive sales and marketing agreement with Baxter Healthcare for our drug product, Enhanze SC™, and filing a 510(k) application for our medical device, Cumulase™,” stated Jonathan Lim, MD, Halozyme’s Chairman and CEO. “Listing on the Amex will provide Halozyme’s shareholders with a desirable market structure and increased visibility in the financial community.”

The approval of the listing of the common stock on Amex is contingent upon Halozyme being in compliance with all applicable listing standards on the date it begins trading on the Amex, and may be rescinded if the Company is not in compliance with such standards.

Halozyme’s hyaluronidase (rHuPH20) is a recombinant form of the naturally occurring human enzyme and is being investigated for its ability to break down hyaluronic acid (HA), the space-filling “gel"-like substance that is a major component of tissues throughout the body. Hyaluronidase that is injected in the skin or in the muscle can temporarily digest the HA gel to enhance the penetration and diffusion of other injected drugs or fluids.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility (CUMULASE™), ophthalmology (ENHANZE SC™), and oncology (CHEMOPHASE™) communities. The company’s portfolio of products in development is based on intellectual property covering the family of human enzymes known as hyaluronidases. The first recombinant human hyaluronidase (rHuPH20) is being developed by Halozyme as a medical device (CUMULASE™), drug enhancement agent (ENHANZE SC™), and therapeutic biologic (CHEMOPHASE™).

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the development and potential commercialization of its product candidates, the commencement of trading on the American Stock Exchange, the Company’s visibility in the financial community and the Company’s compliance with the listing standards of the American Stock Exchange) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company’s reports on Forms 10-KSB, 10-QSB and other filings with the Securities and Exchange Commission.

SOURCE Halozyme Therapeutics, Inc.

David A. Ramsay, Chief Financial Officer of Halozyme
Therapeutics, Inc., +1-858-794-8889, dramsay@halozyme.com; or investors, Ina
McGuinness, imcguinness@lhai.com, or Bruce Voss, both of Lippert/Heilshorn &
Associates, +1-310-691-7100, for Halozyme Therapeutics, Inc.; or media, Kathy
Sweeney, ext. 230, kwitz@mentus.com, or Megan Riggs, ext. 200,
megan@mentus.com, both of Mentus, +1-858-455-5500, for Halozyme Therapeutics,
Inc.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Halozyme Therapeutics, Inc.’s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report or Form 10-K for the most recently ended fiscal year.